Curadh MTR Inc

What Curadh MTR Inc does

Curadh MTR Inc is a privately held, clinical-stage radiopharmaceutical developer founded in February 2022 by Dr. Alison Armour, the former Chief Medical Officer at Endocyte who clinically developed PSMA617 (later approved by Novartis as Pluvicto). The company is headquartered in Chester Springs, Pennsylvania, with operations in Edinburgh, UK, and is focused on developing second-generation molecularly targeted radiation (MTR) therapies designed to treat solid tumors using novel radioisotopes — Actinium-225 (Ac-225), Astatine-211 (At-211), Terbium-161 (Tb-161), and Lutetium-177 (Lu-177) — conjugated to approved or clinically validated oncology targets. Its discovery pipeline targets next-generation biological targets, with a lead program directed at an undisclosed target of high commercial value in solid tumors; first-in-human studies are anticipated in 2025-26 based on recently completed Proof-of-Principle studies.

Curadh operates two interconnected business lines. The first is Curadh Clinical, a wholly-owned advisory division providing strategic and regulatory consultation, data management, statistical services, and clinical operations project management to biotech and pharma clients transitioning from pre-clinical to early-phase clinical development in the MTR space; revenue is generated through professional services engagements. The second is the proprietary MTR pipeline, which the company intends to monetize through licensing, royalties, and co-development arrangements with strategic partners — including long-term isotope supply and co-development agreements with NorthStar Medical Radioisotopes (n.c.a. Ac-225), SHINE Technologies (Lu-177 and Tb-161), and a 2025 Joint Venture with Alpha Fusion covering At-211-based radiopharmaceuticals.

The company emerged from stealth in May 2024 at BioEquity Europe with a substantially expanded transatlantic leadership team: Glenn Kazo as CEO (former co-founder of Enzon and responsible for raising over $500M across three IPOs), Amrik Basran as CSO, Colin Wheeler as Chief Regulatory Officer, Chris Clark as CFO, and Bob Seevers as VP Regulatory/CMC (a 40-year FDA veteran). Curadh serves biotech and pharma companies developing MTR therapies as B2B customers, with end beneficiaries being cancer patients with primary and metastatic solid tumors. The company is privately held with no disclosed equity funding rounds in the available data.

Name

Curadh MTR Inc

Legal name

Curadh MTR Inc.

Website

https://curadhmtr.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Curadh MTR Inc is a privately held, clinical-stage radiopharmaceutical developer founded in 2022, pioneering second-generation molecularly targeted radiation therapies for solid tumors using novel radioisotopes (Ac-225, At-211, Tb-161, Lu-177) and serving biotech and pharma clients through its Curadh Clinical advisory division.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Development

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radiopharmaceutical development
• Molecularly targeted radiation
• Oncology drug development
• Radiopharmaceutical consulting
• Alpha-emitting radioisotopes

Headquarters

HQ city

Chester Springs

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Curadh Clinical Advisory Services: Strategic and regulatory consultation, data management and statistical services support, as well as project management of clinical operations specializing in early-phase clinical development for biotech and pharma companies in the MTR space.
2. Drug Development Partnerships: Revenue generated through strategic partnerships and joint ventures for co-development of radiopharmaceutical products. The company has its own discovery programs and seeks strategic partnerships to develop novel molecules and targets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Curadh MTR Inc is a clinical-stage radiopharmaceutical company developing second-generation molecularly targeted radiation (MTR) therapies for solid tumors using novel radioisotopes (Ac-225, At-211, Tb-161, Lu-177) conjugated to biological targeting molecules. Through its Curadh Clinical division, the company also provides strategic, regulatory, data management, and early-phase clinical trial services to biotech and pharma companies operating in the MTR space.

Product overview

Curadh MTR Inc operates as a clinical research and advisory organization dedicated to developing molecularly targeted radiation (MTR) therapies for solid tumors. The company offers two interconnected service offerings: (1) Curadh Clinical — a specialized advisory division providing strategic/regulatory consultation, data management, and early-phase clinical trial services to biotech and pharma companies in the MTR space; and (2) proprietary MTR therapy development — the company's own pipeline of 2nd generation radiopharmaceuticals targeting solid tumors using novel isotopes (Ac-225, Lu-177, Tb-161, At-211) on validated oncology targets, including discovery programs for next-generation biological targets.

Differentiator

Problem solved

Functional benefit

Products and services

• Curadh Clinical Strategic and regulatory consultancy plus early-phase clinical trial services for biotech and pharma companies in the molecularly targeted radiation (MTR) space, including data management, statistical services, and clinical operations project management.
• Molecularly Targeted Radiation (MTR) Therapy Development Internal discovery and development of second-generation radiopharmaceuticals designed to eradicate solid tumors using novel radioisotopes (Actinium-225, Lutetium-177, Terbium-161, Astatine-211) conjugated to approved or clinically validated oncology targeting molecules.
• Discovery Programs - Next Generation Targets Discovery programs focused on new biological targets best treated by biologicals, including a lead program directed at an undisclosed target of high commercial value with broad applications in solid tumours.

Quantifiable outcome

• PSMA617 acquired by Novartis in 2018 and gained FDA approval in March 2022

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Alpha Fusion, Inc.coreStrategic or Co-development Partner · 1 July 2025Strategic partnership including a Joint Venture to advance global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration combines Alpha Fusion's leading role in At-211 drug discovery and early clinical work in Japan with Curadh's global expertise in radiopharmaceutical development. Joint Venture focuses on clinical development of lead products in the US and developing a pipeline of At-211 products.
• NorthStar Medical RadioisotopescoreTechnology or Integration · 3 January 2024Long-term strategic collaboration to develop and produce novel radiopharmaceuticals for diagnosis and treatment of solid tumor cancers. NorthStar manufactures and distributes patient doses of n.c.a. Ac-225 for Curadh's clinical studies and will provide Ac-225 for commercial use upon FDA Drug Master File submission. NorthStar is building a 52,000 sq ft CDMO facility expected to be operational by January 2025.
• SHINE TechnologiescoreTechnology or Integration · 11 September 2023Expanded long-term supply agreement for medical isotopes including non-carrier-added Lutetium-177 and future supply of Terbium-161. SHINE deploys fusion technology to produce molybdenum-99 and non-carrier-added lutetium-177. The partnership aims to advance cancer therapies using Terbium and Lutetium to target and eliminate cancer cells with precision.
• NorthStar Medical RadioisotopescoreStrategic or Co-development Partner · 29 August 2023Strategic long-term supply agreement for therapeutic radioisotope non-carrier added (n.c.a.) actinium-225 (Ac-225). NorthStar supplies high purity, n.c.a. Ac-225 for Curadh's pioneering MTR programs for treatment of common lethal tumors. This agreement was expanded in January 2024.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Aktis Oncology: Aktis Oncology is a clinical-stage biotechnology company developing targeted alpha radiopharmaceuticals for solid tumors. It is an emerging peer focused on the same Ac-225/alpha-emitter therapeutic modality as Curadh, with comparable stage and similar novel-target strategy.
• Alpha-9 Oncology: Alpha-9 Oncology is an emerging radiopharmaceutical company developing targeted alpha-emitting therapies for solid tumors. It overlaps directly with Curadh on modality (targeted alpha therapy), stage and solid-tumor focus.
• Ratio Therapeutics: Ratio Therapeutics is an emerging radiopharmaceutical company developing targeted radioligand therapies using proprietary linker chemistry and novel radioisotopes for solid tumors. It is a comparable emerging peer on modality (MTR), stage and solid-tumor focus.

Direct peers

• Fusion Pharmaceuticals: Fusion Pharmaceuticals developed targeted alpha therapies using Ac-225 and other linkers before being acquired by AstraZeneca. It is a direct peer on stage, modality (targeted alpha radiotherapy) and isotope (Ac-225) — exactly the space Curadh is pursuing.
• ITM Isotope Technologies Munich: ITM is a leading radiopharmaceutical company producing n.c.a. Lu-177 and developing targeted radionuclide therapies for solid tumors. It directly competes with Curadh in Lu-177-based MTR development and operates an integrated radioisotope supply and drug-development platform.
• Point Biopharma (Lilly): Point Biopharma was a clinical-stage radiopharmaceutical company developing PSMA and solid-tumor radioligand therapies (including Ac-225 programs) before being acquired by Eli Lilly. It is one of the closest direct comparables to Curadh on stage, modality and isotope strategy prior to the acquisition.

Broad incumbents

• Telix Pharmaceuticals: Telix is a publicly listed radiopharmaceutical company commercialising Illuccix (PSMA imaging) and developing therapeutic radiopharmaceuticals for solid tumors across multiple isotopes. Its pipeline and isotope-agnostic platform overlap directly with Curadh's MTR focus on solid-tumor radiotherapy.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with an oncology pipeline spanning PSMA, radiotheranostics, and novel isotopes, including PNT2002 acquired via its Point Biopharma deal. Lantheus directly competes with Curadh in solid-tumor radiopharmaceutical development and operates at substantially greater scale and capital.
• Novartis: Novartis owns Pluvicto (PSMA617) following its 2018 Endocyte acquisition and has built the largest radiopharmaceutical platform in oncology through the subsequent AAA Nuclear Medicine acquisition. Pluvicto was developed by Curadh's founder, making Novartis the closest strategic reference point for Curadh's lead-asset playbook and a dominant incumbent in the same therapeutic modality.
• Bayer (Radiopharmaceuticals / Algeta heritage): Bayer commercialised Xofigo (radium-223) for prostate cancer bone metastases and has continued to invest in radiopharmaceuticals including PSMA-targeted assets via its Algeta heritage. Bayer is a broad incumbent competing in solid-tumor MTR with deep oncology commercial infrastructure.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/curadh-mtr

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curadh MTR Inc